(NASDAQ: CLDX) Celldex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.48%.
Celldex Therapeutics's earnings in 2025 is -$224,532,000.On average, 17 Wall Street analysts forecast CLDX's earnings for 2025 to be -$247,524,279, with the lowest CLDX earnings forecast at -$241,596,987, and the highest CLDX earnings forecast at -$248,388,123. On average, 15 Wall Street analysts forecast CLDX's earnings for 2026 to be -$296,962,686, with the lowest CLDX earnings forecast at -$317,136,745, and the highest CLDX earnings forecast at -$279,785,498.
In 2027, CLDX is forecast to generate -$313,661,438 in earnings, with the lowest earnings forecast at -$373,140,359 and the highest earnings forecast at -$230,247,417.